Skip to Main Content

Paper Details

Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
Clin Cancer Res
3
2022
CDH1, Cancer, ERBB2, ERBB2 mutation, ERBB2 wild type, ERBB2-mutant, ESR1, ESR1 mutations, HER2, Hormone Receptor-positive Metastatic Breast Cancer, KRAS, KRAS mutations, Neoplasia, advanced breast cancer, advanced breast cancer tumors, lobular infiltrating subtype, patients
Author NameAffiliation
Michele L LeNoue-NewtonVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Thomas StrickerVanderbilt University Medical Center
Philippe L BedardUniversity of Toronto, Princess Margaret Cancer Centre
Funda Meric-BernstamMD Anderson Cancer Center
Deborah SchragDana-Farber/Harvard Cancer Center
Eva M LepistoDana-Farber/Harvard Cancer Center
Celeste YuUniversity of Toronto, Princess Margaret Cancer Centre
Mia A Levyand Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Christine M MicheelDivision of Hematology/Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
  • 1 - 9

Datasets

Release 1.2